ArticleMediterranean journal of hematology and infectious diseases2026
Optimizing Treatment, Minimizing Risk: Therapeutic Drug Monitoring in Hematological Malignancies.
Article in Mediterranean journal of hematology and infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The therapeutic landscape of hematological malignancies has expanded rapidly, increasing survival but also exposing patients to pharmacokinetic variability and clinically relevant drug-drug interactions. Therapeutic drug monitoring (TDM) offers a pharmacokinetics-informed strategy to individualize dosing, yet its real-world implementation across drug classes and healthcare settings remains insufficiently characterized. Methods: We conducted an international, cross-sectional online survey (December 2023-February 2024) assessing availability, utilization, and clinical impact of TDM in patients with hematological malignancies. Physicians from multiple specialties reported institutional practices, turnaround times, drug-specific monitoring strategies, and treatment modifications based on TDM results. Results: A total of 209 physicians from 32 countries participated, predominantly from Europe (92%). TDM was widely accessible (97%), mainly performed onsite (79%), and perceived as beneficial by nearly all respondents (99%). Routine TDM was most frequently used for classical agents (methotrexate, cyclosporin A), antifungals, and antibiotics, but substantial interest was reported for targeted therapies, including BCL-2 inhibitors, BCR-ABL tyrosine kinase inhibitors, FLT3 inhibitors, and Bruton tyrosine kinase inhibitors. Treatment was modified based on TDM results by 71% of respondents, with faster turnaround times strongly associated with clinical action. Limited assay availability, delayed reporting, and insufficient clinical evidence were identified as key barriers to broader implementation. Conclusions: TDM is widely available and perceived as clinically useful in the management of hematological malignancies, frequently informing treatment decisions. While firmly established for classical agents and anti-infectives, clinicians express growing interest in extending TDM to targeted therapies. Optimizing turnaround times, expanding assay availability, and integrating pharmacokinetics-informed dosing into clinical trials may further clarify the role of TDM within precision medicine approaches in hematology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.